Global Joint Pain Injection Market: Changing lifestyle and eating habits, high prevalence of calcium deficiency and vitamin D is increasing number of cases of joint pain.

Increasing geriatric population across the globe is boosting the growth of market. For instance, as per the World Population, in 2019, one in eleven is above the age 65 and by 2050 one in six people in the world will be over age 65. Similarly, rising obese population is influencing joint diseases, supporting the growth of market. As per World Health Organization, in 2016, more than 1.9 billion adults where overweight is major cause of knee and lower back pain. High prevalence of calcium deficiency and vitamin D is also increasing number of cases of joint pain. Apart from changing lifestyle and eating habit are increasing prevalence of calcium deficiency and other diseases which is expected to fuel the market growth.

Increasing demand for joint pain injection owing to various players launched new product is expected to drive the market growth. For instance, in 2017, FDA approved first extended-release steroid injection for OA knee pain. Similarly, in 2016, Bioventus launched GELSYN-3 for treatment of knee osteoarthritis pain. Various manufactures invest for geographical expansion is expected to boost the market growth. For instance, January 2019, Bioventus, launched Durolane injection for joint-fluid osteoarthritis (OA) treatment, in Malaysia and has selected Athrotech as its distribution partners.